Monthly Archives: September 2019

Cannabis Firms, Policymakers Must Work Hand-In-Hand, Ex-Canadian Prime Minister Says In MJBizConINT’L Keynote

Cannabis Firms, Policymakers Must Work Hand-In-Hand, Ex-Canadian Prime Minister Says In MJBizConINT’L Keynote

eCann Media is proud to showcase our portfolio of investments and subsidiaries. We have completed numerous investments across multiple verticals and sectors in the cannabis industry. Requesting an invitation will enable the eCann team to consider your eligibility for investment as well help us to identify the opportunities that best fit your needs and investment objectives.

Published at Mon, 23 Sep 2019 12:00:00 +0000

The Politics of SAFE

The Politics of SAFE

The SAFE banking bill would open up banking services for legal cannabis companies. This represents an historic moment for the legal cannabis industry in the United States. For that reason, it is also an historic moment for U.S. consumers.

However, as is typically the case in Congress, elected representatives of both political stripes have been using SAFE as a political football, as detailed in a new Leafly article.

On one side of the aisle, 101 Republicans voted against SAFE in the House. SAFE does nothing more than facilitate banking services for (legal) cannabis companies in states that have authorized legal cannabis.

Do these Republicans not support States’ rights?

Currently, these legal cannabis companies are forced to operate on a cash-only basis. Cash-based transactions have been discouraged in other industries because they facilitate the presence of Organized Crime.

Do these Republicans support Organized Crime?

On the other side of the aisle, Democrats have also sought to politicize this legislation. Instead of being satisfied with this important incremental step in the national legalization of cannabis in the United States, some Democrats are protesting that it’s not enough.

These Democrats (including Senate Minority Leader Chuck Schumer) want everything to be included today in any federal legislation put to a vote.
 

“Congress should not enact banking reform alone and think the job is done,” Senate Majority Leader Chuck Schumer (D-NY) said on Twitter last week. “We need decriminalization at the federal level, criminal justice reform, and investment in opportunity for minority & women-owned small businesses.”

This is the United States.

What happens if a political party does not control both the House and the Senate (and the White House), but attempts to push through legislation that represents a wish-list? Nothing gets done.

Some Democrats are prepared to make the legal cannabis industry in the U.S. a hostage in negotiations – while they attempt to score political points.

SAFE has moved to the Senate. Senate Republicans are now in the spotlight. Will they behave any better than the House Republicans and the prominent Democrats that have already tried to jeopardize this bill for partisan purposes?

In the Senate, Majority Leader Mitch McConnell has famously dubbed himself “the Grim Reaper”. He has vowed to prevent any Democrat-sponsored bill from ever reaching a vote. Other Senate Republicans may also decide to stand against SAFE for political reasons alone.

Anticipating this, the House added a key amendment to SAFE that broadens the bill to fully include legal cannabis and legal hemp businesses.

Mitch McConnell has always been strongly opposed publicly to any legislation which furthers “marijuana” legalization. But Mitch McConnell supports legalized hemp and the hemp industry in his home state.

Will this House amendment be the proverbial ‘spoonful of sugar’ necessary to get the Grim Reaper to swallow this medicine that is badly needed by the legal cannabis industry? Or, will McConnell make this even more nakedly political – and block SAFE even though it also advances the legal hemp industry?
 

Despite positive signals by Sen. Crapo of Idaho and a small group of Republicans, including Sens. Rand Paul (KY) and Lisa Murkowski (AK), there is skepticism about whether the Senate’s GOP leaders would even let the bill come to a vote. In July, the Senate Committee on Banking, Housing, and Urban Affairs held a hearing on the challenges of cannabis banking. Crapo, the committee chair, was the only Republican senator in attendance.

The United States federal government has been playing politics with cannabis for more than 80 years. Indeed, the cannabis Prohibition it imposed is the underlying cause behind the current vaping health issue that has hospitalized hundreds of Americans and resulted in eight fatalities (to date).

Playing politics with cannabis legalization is playing politics with the lives of Americans. It always has been. How many Americans have died unnecessarily because they were deprived of the many potent medicinal/health benefits of the cannabis plant?

It’s time the federal government stopped playing politics with cannabis. It’s a naïve hope. But, occasionally, Washington surprises Americans by doing what’s right rather than doing what’s easy.

As SAFE moves to the Senate, the U.S. cannabis industry and cannabis investors are hoping that this is one of those rare occasions.
 

Published at Mon, 30 Sep 2019 16:43:31 +0000

SAFE Banking Act Clears U.S. House, Massachusetts Bans All Vape Sales for Four Months: Week in Review

SAFE Banking Act Clears U.S. House, Massachusetts Bans All Vape Sales for Four Months: Week in Review

In an exciting mainstream media report yesterday, NBC News highlighted a groundbreaking new development from the lab of Dr. Raphael Mechoulam, the godfather of cannabis chemistry: cannabinoid acids.

Dr. Mechoulam, an organic chemist and professor of medicinal chemistry based at the Hebrew University in Jerusalem, led the first team of researchers to discover and synthesize the two primary medicinal compounds in cannabis, CBD and THC, back in 1963 and 1964, respectively (1). He began the first clinical trials on CBD and epilepsy in 1980, but it would be nearly 40 years before FDA approval, in the form of GW Pharmaceuticals’ Epidiolox, would grant access to patients seeking better treatment alternatives in 2018 (2).

On Monday, while presenting at this year’s CannMed Conference in Pasadena, Calif., Mechoulam and his team announced that they had “developed a process for creating synthetic, stable acids” ready to be licensed for drug development and subsequent research.

Until now, acidic cannabinoids, including THCA and CBDA, have been notoriously difficult to source and sustain. These raw-plant compounds are the primary constituents of the cannabis plant—with “activated” molecules only popping up in small numbers—and are readily converted into their neutral forms, THC and CBD, with the addition of heat and time, a process known as “decarboxylation,” making stable formulations easier said than done (3).

Cannabinoid acids have shown great therapeutic promise without risk of intoxication, in the case of THC, and with greater water solubility and bioavailability than their activated progeny (4, 5).  

For example, as the NBC article pointed out, researchers at the University of Guelph have shown CBDA to be “1,000 times more potent than CBD in reducing acute nausea” (6) and this raw compound also demonstrates remarkable COX-2 inhibition that could prove valuable in reducing inflammatory pain without the risk of gastrointestinal injury, as is seen with NSAID applications (7).

One of the most beneficial aspects of THCA is its ability to act therapeutically without the intoxicating effects associated with THC, leaving more wiggle room in its therapeutic window. Additionally, THCA has demonstrated potent neuroprotective benefits in an in vitro model of Parkinson’s disease and exciting antineoplastic (anti-cancer) results in several prostate and breast cancer models (5).

According to the NBC article, Mechoulam’s research on acidic cannabinoids is in partnership with “a startup called EPM, six universities in Israel, the U.K. and Canada, the world’s largest topical cream company, and a publicly traded laboratory company”—the U.S. is still out of the picture due to restrictive research access and the prohibitory scheduling of cannabis compounds. As EPM co-founder, Reshef Swisa, expressed to NBC, he sees the first applications for the acidic compounds likely going towards topical products targeting symptoms of psoriasis with an eye on Phase 1 FDA testing within six to twelve months.

While this news is encouraging, FDA approval doesn’t move quickly and there are still many years ahead of us before we see a marketable product from the pharmaceutical industry making its way into the hands of the people who need it now. A good reminder that all you need is access to the raw plant and a juicer to find relief today.

Published at Sat, 28 Sep 2019 14:00:00 +0000

Choom-branded Cannabis Retail Store Licensed to Open in Westlock, Alberta

Choom-branded Cannabis Retail Store Licensed to Open in Westlock, Alberta

Choom™ (CSE: CHOO; OTCQB: CHOOF), an emerging adult use cannabis company that has secured one of the largest national retail networks in Canada, is pleased to announce that an Alberta provincially approved cannabis retail licensee (“Licensee”) is opening a cannabis retail store in Westlock, Alberta operating under the Choom brand.

Choom Holdings Inc. (CNW Group/Choom Holdings Inc.)

“We look forward to welcoming the community of Westlock as we share our unique retail experience with the opening of another Choom-branded cannabis store in Alberta.” said Corey Gillon, President of Choom.  “This location represents another milestone achieved in our rapid growth strategy; we are thrilled to further expand our cannabis retail network throughout Alberta.”

The store is set to open on Saturday, September 28th, 2019.  The new store is located 10140-107th Street Westlock, AB, T7P 1X3. Opening hours are 10am to 6pm until Oct. 5th.  Ongoing hours after Oct 5th are:  10am – 8pm (Monday to Wednesday), 10am10pm (Thursday – Saturday), and 10am7pm (Sunday).  For more information, visit choom.ca.

In addition to a licensing agreement with the Licensee, Choom has entered in a purchase agreement with the Licensee, pursuant to which, subject to receipt of approval from Alberta’s regulatory bodies, Choom will acquire the Westlock store. Choom has passed its due diligence and received approval from Alberta Gaming Liquor & Cannabis to operate in the Province of Alberta.

Say hello to Choom
Choom™ is an emerging adult use cannabis company whose mission is to establish one of the largest retail networks in Canada. The Choom brand is inspired by Hawaii’s “Choom Gang”—a group of buddies in Honolulu during the 1970’s who loved to smoke weed—or as the locals called it, “Choom”. Evoking the spirit of the original Choom Gang, our brand caters to the Canadian adult use market with the ethos of ‘cultivating good times’. Choom™ is focused on delivering an elevated customer experience through our curated retail environments, offering a diversity of brands for Canadians across a national retail network.

“Chris Bogart”
CEO

Cautionary Statement:

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking information        
This news release contains forward-looking information relating to the Company’s proposed activities and other statements that are not historical facts. Forward-looking information relates to management’s future outlook and anticipated events or results, and include statements or information regarding the future plans or prospects of the Company. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. These factors include risks and uncertainties associated with or arising as a result of delays in obtaining or an inability to obtain required regulatory approvals, access to sufficient quantities of cannabis, the results of diligence investigations, the actions of third parties, the results of negotiations with third parties, developments in the cannabis sector, the ability to access sufficient capital from internal and external sources, reliance on key personnel, regulatory risks and delays and other risks and uncertainties discussed in the management discussion and analysis section of the Company’s interim and most recent annual financial statement or other reports and filings, including those made with the CSE and applicable Canadian securities regulators. There can be no assurance that such forward looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward looking information.

SOURCE Choom Holdings Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2019/27/c3396.html

Choom Holdings Inc., Corey Gillon, President, T: 604.683.2509, F: 604.683.2506, E: corey@choom.ca; Chris Bogart, CEO, T: 604.683.2509, F: 604.683.2506, E: chris@choom.caCopyright CNW Group 2019

Source: Canada Newswire (September 27, 2019 – 7:00 AM EDT)

News by QuoteMedia
www.quotemedia.com

Published at Fri, 27 Sep 2019 11:04:01 +0000

Diego Pellicer Worldwide Inc (OTCMKTS:DPWW) Signs An LOI To Acquire Denver Based 2,287 Sq. Ft. Marijuana Infused Product Facility

Diego Pellicer Worldwide Inc (OTCMKTS:DPWW) Signs An LOI To Acquire Denver Based 2,287 Sq. Ft. Marijuana Infused Product Facility

Diego
Pellicer Worldwide Inc (OTCMKTS:DPWW)
has announced signing a Letter of
Intent to acquire Denver based 2,287 Sq. Ft. MIP (marijuana-infused product)
manufacturing facility. The new state of the art facility features a walk-in
vault, office, and a class 1 facility. The new facility helps the company to
manufacture 2,650 pounds of cannabis annually for recreational and medical use.

Diego Pellicer would have the
capability to produce 4,500 pounds of cannabis annually with the takeover of
this second manufacturing facility. The company announced the signing of LOI on
September 10, 2019. Chief Executive Officer of Diego Pellicer, Ron Throgmartin
said this strategic acquisition makes Pellicer a vertically integrated
marijuana firm. The company is into cultivation and production to recreational
and medical sales. The latest stint is a perfect fit for the expanded business
model of Diego Pellicer.

Manufactures
premium concentrates

After receipt of nod from the Colorado Marijuana Enforcement
Division, Diego Pellicer would engage in the production of marijuana-infused
products and premium concentrates. The deal is also subject to compliance with
House Bill 19-1090. The company would sell world-class marijuana-infused
products at its retail locations across the world. According to CEO, the
takeover of the facility is a significant leap in its stride to expand the
business in states that permit recreational and medical cannabis operations.

Deal includes cannabis
extraction machine

As part of the non-binding LOI, Diego Pellicer would receive
a number of machines. These include a cannabis extraction machine together with
fumigation hoods, recovery pump, flower preparation room, rosin press, isolated
grid room, and vacuum oven.

Competitively priced
finest products

The customers can expect the finest products from branded
stores of Diego Pellicer. They will also enjoy exceptional customer service.
You can buy experts selected, and Diego Pellicer cultivated premium quality
products irrespective of the location.

Record Sales in July

Diego Pellicer has announced record gross sales in July 2019
from its licensee in Denver. It is an increase of 8.56% since April 2019.
According to the CEO, the success is on the backdrop of offering premium
quality products backed by excellent customer service. The company expanded its
customer base by providing cannabis products at all price points.

Published at Fri, 27 Sep 2019 12:01:38 +0000

Pro Snowboarder and Film Maker Travis Rice Partners with Leading CBD Brand, HempFusion

Pro Snowboarder and Film Maker Travis Rice Partners with Leading CBD Brand, HempFusion

HempFusion (“the Company”), a leading Hemp/CBD company in the United States with distribution of its family of brands to over 3,400 retailers across 47 states, is pleased to announce a first of its kind partnership with legendary action sports athlete and global action film icon Travis Rice, as the latest HempFusion brand ambassador.

Logo: HempFusion (CNW Group/Hemp Fusion)

Travis is one of the most prolific snowboarders of all time, having won gold medals in over 23 competitions including the X-Games, Red Bull Supernatural, Icer Air, Quicksilver Natural Selection and many more. Travis has been named Snowboarder Magazine Rider of the Year and National Geographic Adventurer of the Year and has been featured in over twenty snowboarding films. In 2013, Rice was named the best contemporary snowboarder in the world by RedBull. HempFusion is proud to partner with Mr. Rice and looks forward to continuing to provide him with a range of premium hemp-based CBD products based on the Company’s proprietary Whole Food Hemp Complex™ to help him perform at his best.

“The integrity of HempFusion’s CBD products is clear, they have been a game changer for me,” commented Travis Rice. “From the Twist products in my smoothies to the to the Liquid Hemp Extract before bed, for years HempFusion’s products have supported my training and lifestyle. I’m excited to partner with the brand that I have been a fan of as I continue to explore creative outlets and improve my health to play in nature. This is going to be a great collaboration, Stay tuned!” continued Rice.

Travis shifted gears in 2008 adding film making to his repertoire with the release of That’s It That’s All, followed shortly thereafter with the award-winning The Art of Flight in 2011. Rice’s ground-breaking films also include The Fourth Phase and Depth Perception and have redefined snowboarding, making Rice one of the most prolific athletes and film makers in action sports history.

“We couldn’t be more happy to partner with the legendary Travis Rice, and support his active lifestyle and rigorous travel schedule with our premium CBD products.” commented Ian deQueiroz, CEO of HempFusion. “Not only does Travis value integrity, hard work, and physical, spiritual and mental health, he embodies the balance HempFusion’s customers seek to achieve and we are proud to have him as an official brand ambassador. I’m looking forward to seeing what he dreams up this winter!”

Some of Travis’ favorite HempFusion products can be found by clicking here.

ABOUT HEMPFUSION

HempFusion is a premium hemp-based cannabidiol (“CBD”) wellness Company with distribution of its family of brands to over 3,400 retailers across 47 US states. The Company is engaged in the advancement of therapeutic benefits of industrial hemp extract and striving to maintain the highest level of compliance in the industry. HempFusion’s wide variety of 25+ full spectrum CBD products are sourced from quality phytocompounds manufactured under strict cGMP standards designed to attain maximum efficacy and safety. HempFusion’s primary focus is formulating and marketing premium consumer-specific product lines with various delivery methods, across multiple distribution platforms. The Company’s CBD products are based on a proprietary Whole Food Hemp Complex ™ and are available through independently owned and national chain health food stores, or by visiting www.hempfusion.com.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties, and other factors that may cause actual events to differ materially from current expectation. Important factors — including the availability of funds, the results of financing efforts and the parties’ due diligence reviews, and general market conditions — that could cause actual results to differ materially from the Company’s expectations. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

HempFusion is pleased to announce a first of its kind partnership with legendary action sports athlete and global action film icon Travis Rice, as the latest HempFusion brand ambassador. (CNW Group/Hemp Fusion)

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/pro-snowboarder-and-film-maker-travis-rice-partners-with-leading-cbd-brand-hempfusion-300926783.html

SOURCE Hemp Fusion

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2019/27/c7016.html

Investor Relations, Name: Spencer MacLean, Email: smaclean@hempfusion.com, Phone: 416-803-5638, Web: www.hempfusion.com/investorsCopyright CNW Group 2019

Published at Fri, 27 Sep 2019 11:12:42 +0000

How You Can Start Making Money From Hemp

How You Can Start Making Money From Hemp

eCann Media is proud to showcase our portfolio of investments and subsidiaries. We have completed numerous investments across multiple verticals and sectors in the cannabis industry. Requesting an invitation will enable the eCann team to consider your eligibility for investment as well help us to identify the opportunities that best fit your needs and investment objectives.

Published at Thu, 26 Sep 2019 16:00:00 +0000

Yield Growth Corp. Is Deploying It’s Global CBD Strategy Across Multiple Product Verticals At An Impressive Rate

Yield Growth Corp. Is Deploying It’s Global CBD Strategy Across Multiple Product Verticals At An Impressive Rate

Demand for products that contain cannabidiol (CBD) continues to increase and we have seen a variety of industries start to incorporate the cannabinoid into everyday types of products. We recently came across a story that featured a butcher who started adding CBD to sausages and ended up selling out of product that day. Over time, we believe that CBD will be treated as a supplement and will be included in tens of thousands of products.

Going forward, we expect to see increasing demand for CBD products and this is a trend to be excited about. For several years, we have been laser focused on the CBD industry and have been working to identify companies that are positioned to capitalize on this burgeoning market. Europe is one of the markets that we have been especially excited about due to attractive economics associated with the sale of CBD products and the size of the population.

When compared to North America, Europe has twice the population and a much less mature industry. Due to this, the price of CBD is much higher in Europe when compared to North America and we find this to be significant. The Yield Growth Corp. (BOSS.CN) (BOSQF) has been laser focused on the European CBD market and this is an opportunity that we have been closely following.

Yield Growth: An Emerging European CBD Opportunity

Last week, Yield Growth recorded a significant development as it relates to the European market and announced a distribution and licensing agreement with Melorganics Hellas for European rights to six product formulas for CBD infusion for a fee of $900,000. Under the agreement, Yield has agreed to license to Melorganics (in perpetuity) the non-exclusive rights to formulas and know-how to manufacture and distribute CBD foot cream, CBD body oil, CBD muscle relief balm, CBD body exfoliant, CBD relief gel and CBD hand cream.

The formulas may be developed by Melorganics into products infused with CBD and other cannabinoids and distributed throughout the European Union under one brand to be developed by Melorganics. According to the agreement, Yield Growth will have approval on the brand and packaging of the products, and we will be monitoring how the companies are able to execute on this opportunity.

Under the agreement, Melorganics will issue units to cover the $900,000 fee that is owed to Yield Growth, which represents approx. 18% of Melorganics. Yield Growth also has the right to appoint a Director to Melorganics’ Board of Directors and we find these terms to be favorable for the company.

Once this agreement is completed, Yield Growth has also agreed to grant Melorganics exclusive distribution rights to the Wright & Well brand of CBD products in Greece and Cyprus for a term of two years and for a fee of $100,000. The fee will be payable after a definitive distribution agreement is signed and after at least 3 Wright & Well products have been registered for sale within the European Union.

Over the next year, we expect to see the companies expand on this relationship and are bullish on the potential value associated with this agreement. Since Yield Growth has a considerable ownership interest in Melorganics, we expect this to be a major focal point for the business and will monitor how the team are able to drive this partnership forward. As previously announced, Melorganics was appointed as the exclusive retail distributor and non-exclusive e-commerce distributor for Yield Growth’s Urban Juve products in Greece and Cyprus.

If Melorganics wants to maintain its exclusivity in Greece and Cyprus, it must purchase at least $300,000 of Urban Juve products of in Year 1 and $500,000 in each subsequent year. Yield Growth is currently in the process of registering all of its Urban Juve products for sale in the European Union with 2 products already approved and 9 more that are expected to complete registration in the fall. We are favorable on the structure of this agreement as it requires Melorganics to execute to maintain its exclusivity on in Greece and Cyprus.

Issued a Compliance Certificate to Sell Lip Balm in the EU

A few weeks ago, Yield Growth reported a major milestone after Urban Juve Lip Balm with Hemp Oil was approved to be sold in the European market. Urban Juve’s Responsible Person in Europe, Biorius, has issued a compliance certificate for the product in accordance with EU regulations and we find this to be significant.

Urban Juve’s Lip Balm with Hemp Oil is one of the brand’s top-selling products. The lip balm will be featured in Vogue Beauty Highlights in October, introducing the product to an audience of 4.1 million readers. Urban Juve is manufacturing 250,000 units of its lip balm, which will be ready in September and we are favorable on the marketing strategy in place to generate awareness for the brand. We are excited about this aspect of the story and believe that this approval represents a major development for the business.

Pursuant to EU regulations, Yield Growth retained Biorius to act as its Responsible Person for Urban Juve. After a rigorous review of each ingredient in the lip balm, Biorius issued a certificate of compliance, confirming that Urban Juve Ultra Hydrating Lip Balm is now registered with the EU. Urban Juve now has two products registered with the EU and expects to have nine more products registered by early fall. The launching of new products represents an attractive growth opportunity for Yield Growth and we will be monitoring how the market responds to the launch.

A North American Growth Story to be Watching

Although we are very excited about the European market for Yield Growth, the North American market represents an attractive CBD market and we are favorable on the recent developments. Currently, Yield Growth has more than 35 products registered with Health Canada and 12 US patents pending. The company’s proprietary formula library includes more than 200 personal and skin care formulas, health supplements, and therapeutic formulas, plus eight beverage formulas.

In early July, Yield Growth announced that 130 retail locations across North America have agreed to sell Urban Juve products. The locations are diverse geographically, and will bring luxury, hemp-powered skincare products to new markets. These locations were strategically selected to help boost brand awareness in this key demographic and will monitor how the team continues to execute.

Urban Juve appeals to a savvy, health-conscious target market and we are excited to see the company gain market share across this demographic. In addition to the 130 retail locations, Yield Growth also secured events and locations for a series pop up shops that will sell Urban Juve products. By the end of the year, Urban Juve plans to have distribution in more than 500 stores and we are bullish on the amount of revenue that can be generated through this network.

A High-Growth Story that is Flying Under the Radar

According to Jefferies, the CBD beauty industry is expected to reach US $25 billion within 10 years and that it could account for 10 – 15% of global skincare sales. Jefferies said, the Global Beauty & Personal Care market neared $465 billion in 2017 and is ripe for disruption from Cannabis-based products. We are favorable on the potential that Yield Growth has to capture market share and will monitor how the team continues to execute across the board.

One of the reasons we are confident in Yield Growth’s ability to execute is due to the management team in place. The company is led by executives that have diverse backgrounds and proven track records of success. Yield Growth recently appointed Tamara Melck as Chief Operating Officer who played a key role in the growth of Canadian fashion retailer Aritzia (ATZ.TO), serving as the Vice President, Corporate Operations and Executive Vice President, People & Culture.

When looking at any cannabis company, the most important aspect of the business is the management team, and this is an area where Yield Growth excels. We believe that the strength of the leadership team has played an important role in the success of Urban Juve and believe that Tom Bond (former COO of MAC Cosmetics) and Jeff Smith (former Chairman of Johnson & Johnson) will continue to play an instrumental role in the long-term success of the operation.

A Company with Catalysts for Growth

Another reason we are excited about Yield Growth is due to the potential catalysts for growth. The company has a visible growth strategy and going forward, the name of the game is execution. In the coming months, Yield Growth plans to launch several CBD product lines and will target the US and Europe. The Brightfield Group recently announced market intelligence stating that the European CBD market will boom with 400% growth through 2023.

From a distribution standpoint, Yield Growth has been nothing short of a major success and we are bullish on this aspect of the business. In regard to Urban Juve, the company has an online platform and the products are sold in brick and mortar stores in North America. Yield Growth is targeting strategic markets (LA, San Fran, NY, Toronto and Vancouver) and we are bullish on the growth prospects associated with these markets.

An exciting aspect of the existing distribution strategy is related to the signed marketing and sales alliance that Yield Growth has with ipsy, the world’s largest beauty community of 3 million+ monthly members, to include Urban Juve’s line of hemp-based beauty products in its Glam Bag. The products are already available for purchase on Shopper, ipsy’s exclusive ecommerce marketplace, and we are favorable on this relationship.

Earlier this month, Yield Growth announced plans to launch its Urban Juve in at the upcoming ipsy Live event in Manhattan, New York, in mid-October. Urban Juve is anticipating a high level of social media engagement and will be included on multi-branded posts, which have the potential to reach ipsy’s 2.3 million Instagram followers and 5.4 million Facebook followers. We expect the event to generate significant awareness for the hemp skin care line and will monitor how this serves as a potential catalyst for sales.

Urban Juve is teaming up with a New York based agency to create an interactive experience at its booth at ipsy Live to educate attendees by giving Ayurvedic-based skin assessments. The timing of this event coincides with the launch of Urban Juve’s Ultra-Hydrating Lip Balm which will be included in gift bags for the 4,000 event attendees. The interactive booth and influencer experience will be replicated throughout North America as Urban Juve unveils its Pop Up and Retail strategy.

Through a multi-faceted marketing strategy and through strategic partners, Yield Growth is well positioned to record strong growth and penetrate major markets across North America and Europe. We are excited about the relationships in place and believe that this aspect of the story is underappreciated by the street.

To stay up to date with Yield Growth, please reach out to support@technical420.com and we will add you to our distribution list.

Pursuant to an agreement between StoneBridge Partners LLC and The Yield Growth Corp. we have been hired for a period of 180 days beginning July 23, 2019 and ending January 23, 2020 to publicly disseminate information about (BOSS) including on the Website and other media including Facebook and Twitter. We are being paid $7,500 per month (BOSS) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero (0) shares of (BOSS), which we purchased in the open market. We plan to sell the “ZERO” shares of (BOSS) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (BOSS) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share

Share - Facebook


Share - Twitter

Published at Wed, 25 Sep 2019 11:24:31 +0000

Cronos Group’s (NASDAQ:CRON) And MediPharm Labs Corp (OTCMKTS:MEDIF) Sign A Contract Manufacturing Deal

Cronos Group’s (NASDAQ:CRON) And MediPharm Labs Corp (OTCMKTS:MEDIF) Sign A Contract Manufacturing Deal

MediPharm Labs Corp (OTCMKTS:MEDIF) entered a contract manufacturing deal for packaging and filling of vaporizers for Cronos Group’s (NASDAQ:CRON) recreational use brand, COVE subject to approval form Health Canada.

CMA deal between
MediPharma and Cronos Group

MediPharm is a wholly-owned Cronos Group subsidiary that will be producing premium cannabis vaporizer devices for the company. With the signed contract manufacturing agreement, MediPharm will use its proprietary equipment and knowledge to offer filling services of premium quality formulate cannabis concentrate for Cronos. Equally, the subsidiary will provide packaging and labeling services to required standards for its parent company. The CMA has an initial term of two years, but this has an option of renewal once the term expires.

Pat McCutcheon, the CEO of MediPharm Labs, stated that just a day
before the legalization of concentrates in Canada they added Cronos Group to
the company’s growing white-label platform. He added that MediPharm would
leverage its technology, expertise, as well as its large-scale vape filling
abilities. This will help assist Cronos Groups in the delivery of premiums,
purity assured as well as Health Canada approved cannabis derivative product.
This will help Cronos Group in advancing its industry-leading status.

This is the second time the companies are collaborating this year. In May they entered a private label large scale resin supply agreement as well as a cannabis concentrate program deal that will see the companies work together.

The deal offers Cronos a
chance to create premium products

Cronos Group CEO, Mike Gorenstein, said that the collaboration with
MediPharm will provide an option and quality that they are seeking as they look
to introduce their proprietary vape devices. He added that Cronos Group has the
dedication and commitment to ensure it continues to lead the cannabis industry
with the introduction of cannabis derivatives to the burgeoning Canadian
marketplace.

Cronos Group aims at offering customers the best experience through
the delivery of premium cannabis products. The company is growing its brand portfolio
which includes two adult-use brands, Spinach and COVE as well as PEACE
NATURALS.

Published at Tue, 24 Sep 2019 12:01:39 +0000